Data Points to Potential for Patient Centricity in Rare Disease Trial Success
Global orphan drug sales are on the rise. To dodge potential pitfalls associated with reaching ultra-rare populations, mapping patient pathways, reducing trial burden and partnering with advocacy groups is crucial
